Compliance certificate under reg. 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals Ltd has submitted a routine compliance certificate to BSE for the quarter ended 31 March 2025. The certificate, based on confirmation from its Registrar and Transfer Agent Aarthi Consultants Pvt Ltd, states that all share certificates received for dematerialization during January–March 2025 were properly mutilated, cancelled, and the depository was recorded as the registered owner within the 15-day SEBI-mandated timeline. It also confirms that the dematerialized securities remain listed on the stock exchange. The filing was signed by Executive Director Dhananjaya Alli on 21 April 2025. No business, financial, or operational details are disclosed in this submission.
This is a routine procedural filing required by SEBI and carries no material impact on the company's financials, operations, or share price. Investors can view it as confirmation that the company's share transfer and dematerialization process is functioning in line with regulations.